Pharma & Healthcare
Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Research Report 2026
- Jan 17, 26
- ID: 687370
- Pages: 116
- Figures: 112
- Views: 9
This report delivers a comprehensive overview of the global Nectin-4-Directed Antibody Drug Conjugates (ADC) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nectin-4-Directed Antibody Drug Conjugates (ADC). The Nectin-4-Directed Antibody Drug Conjugates (ADC) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Nectin-4-Directed Antibody Drug Conjugates (ADC) market comprehensively. Regional market sizes by Type, by Application, by Payload Mechanism, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Nectin-4-Directed Antibody Drug Conjugates (ADC) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Astellas
Innate Pharma
Corbus Pharmaceuticals
BioAtla
Eli Lilly
Adcentrx Therapeutics
Mabwell
Jiangsu Hengrui
Cspc Holdings
Segment by Type
Cleavable Linkers
Non-cleavable Linkers
Segment by Payload Mechanism
Microtubule inhibitors
Topoisomerase Inhibitor
Others
Segment by Antibody
Humanized IgG1
Fc Silencing IgG1
by Application
Bladder Cancer
Esophageal Cancer
Triple-negative Breast Cancer
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Payload Mechanism, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Nectin-4-Directed Antibody Drug Conjugates (ADC) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Nectin-4-Directed Antibody Drug Conjugates (ADC) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Nectin-4-Directed Antibody Drug Conjugates (ADC) market comprehensively. Regional market sizes by Type, by Application, by Payload Mechanism, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Nectin-4-Directed Antibody Drug Conjugates (ADC) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Astellas
Innate Pharma
Corbus Pharmaceuticals
BioAtla
Eli Lilly
Adcentrx Therapeutics
Mabwell
Jiangsu Hengrui
Cspc Holdings
Segment by Type
Cleavable Linkers
Non-cleavable Linkers
Segment by Payload Mechanism
Microtubule inhibitors
Topoisomerase Inhibitor
Others
Segment by Antibody
Humanized IgG1
Fc Silencing IgG1
by Application
Bladder Cancer
Esophageal Cancer
Triple-negative Breast Cancer
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Payload Mechanism, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Nectin-4-Directed Antibody Drug Conjugates (ADC) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Nectin-4-Directed Antibody Drug Conjugates (ADC) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Overview
1.1 Product Definition
1.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type
1.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type: 2025 vs 2032
1.2.2 Cleavable Linkers
1.2.3 Non-cleavable Linkers
1.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Payload Mechanism
1.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism: 2025 vs 2032
1.3.2 Microtubule inhibitors
1.3.3 Topoisomerase Inhibitor
1.3.4 Others
1.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Antibody
1.4.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody: 2025 vs 2032
1.4.2 Humanized IgG1
1.4.3 Fc Silencing IgG1
1.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application
1.5.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application: 2025 vs 2032
1.5.2 Bladder Cancer
1.5.3 Esophageal Cancer
1.5.4 Triple-negative Breast Cancer
1.5.5 Others
1.6 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size Estimates and Forecasts
1.6.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021–2032
1.6.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021–2032
1.6.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competition by Manufacturers
2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Nectin-4-Directed Antibody Drug Conjugates (ADC), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Product Types and Applications
2.7 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Date of Entry into the Industry
2.8 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competitive Situation and Trends
2.8.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Players Market Share by Revenue
2.8.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Scenario by Region
3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2021–2032
3.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2021–2026
3.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2027–2032
3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021–2032
3.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021–2026
3.3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2027–2032
3.4 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country
3.4.1 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)
3.4.3 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country
3.5.1 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)
3.5.3 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Region
3.6.1 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (2021–2032)
3.6.3 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country
3.7.1 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)
3.7.3 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country
3.8.1 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021–2032)
4.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021–2026)
4.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2027–2032)
4.1.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021–2032)
4.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2021–2032)
4.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2021–2026)
4.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2027–2032)
4.2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021–2032)
4.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021–2032)
5.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021–2026)
5.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2027–2032)
5.1.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021–2032)
5.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2021–2032)
5.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2021–2026)
5.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2027–2032)
5.2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2021–2032)
5.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Astellas
6.1.1 Astellas Company Information
6.1.2 Astellas Description and Business Overview
6.1.3 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.1.5 Astellas Recent Developments/Updates
6.2 Innate Pharma
6.2.1 Innate Pharma Company Information
6.2.2 Innate Pharma Description and Business Overview
6.2.3 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.2.5 Innate Pharma Recent Developments/Updates
6.3 Corbus Pharmaceuticals
6.3.1 Corbus Pharmaceuticals Company Information
6.3.2 Corbus Pharmaceuticals Description and Business Overview
6.3.3 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.3.5 Corbus Pharmaceuticals Recent Developments/Updates
6.4 BioAtla
6.4.1 BioAtla Company Information
6.4.2 BioAtla Description and Business Overview
6.4.3 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.4.5 BioAtla Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Company Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Adcentrx Therapeutics
6.6.1 Adcentrx Therapeutics Company Information
6.6.2 Adcentrx Therapeutics Description and Business Overview
6.6.3 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.6.5 Adcentrx Therapeutics Recent Developments/Updates
6.7 Mabwell
6.7.1 Mabwell Company Information
6.7.2 Mabwell Description and Business Overview
6.7.3 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.7.5 Mabwell Recent Developments/Updates
6.8 Jiangsu Hengrui
6.8.1 Jiangsu Hengrui Company Information
6.8.2 Jiangsu Hengrui Description and Business Overview
6.8.3 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.8.5 Jiangsu Hengrui Recent Developments/Updates
6.9 Cspc Holdings
6.9.1 Cspc Holdings Company Information
6.9.2 Cspc Holdings Description and Business Overview
6.9.3 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.9.5 Cspc Holdings Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Industry Chain Analysis
7.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Production Mode & Process Analysis
7.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales and Marketing
7.4.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Channels
7.4.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors
7.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) Customer Analysis
8 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Dynamics
8.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Industry Trends
8.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Drivers
8.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Challenges
8.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type
1.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type: 2025 vs 2032
1.2.2 Cleavable Linkers
1.2.3 Non-cleavable Linkers
1.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Payload Mechanism
1.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism: 2025 vs 2032
1.3.2 Microtubule inhibitors
1.3.3 Topoisomerase Inhibitor
1.3.4 Others
1.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Antibody
1.4.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody: 2025 vs 2032
1.4.2 Humanized IgG1
1.4.3 Fc Silencing IgG1
1.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application
1.5.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application: 2025 vs 2032
1.5.2 Bladder Cancer
1.5.3 Esophageal Cancer
1.5.4 Triple-negative Breast Cancer
1.5.5 Others
1.6 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size Estimates and Forecasts
1.6.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021–2032
1.6.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021–2032
1.6.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competition by Manufacturers
2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Nectin-4-Directed Antibody Drug Conjugates (ADC), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Product Types and Applications
2.7 Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Date of Entry into the Industry
2.8 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competitive Situation and Trends
2.8.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Players Market Share by Revenue
2.8.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Scenario by Region
3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2021–2032
3.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2021–2026
3.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region: 2027–2032
3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021–2032
3.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021–2026
3.3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2027–2032
3.4 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country
3.4.1 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)
3.4.3 North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country
3.5.1 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)
3.5.3 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Region
3.6.1 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (2021–2032)
3.6.3 Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country
3.7.1 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)
3.7.3 Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Facts & Figures by Country
3.8.1 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021–2032)
4.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021–2026)
4.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2027–2032)
4.1.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021–2032)
4.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2021–2032)
4.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2021–2026)
4.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2027–2032)
4.2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021–2032)
4.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021–2032)
5.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021–2026)
5.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2027–2032)
5.1.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021–2032)
5.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2021–2032)
5.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2021–2026)
5.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2027–2032)
5.2.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2021–2032)
5.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Astellas
6.1.1 Astellas Company Information
6.1.2 Astellas Description and Business Overview
6.1.3 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.1.5 Astellas Recent Developments/Updates
6.2 Innate Pharma
6.2.1 Innate Pharma Company Information
6.2.2 Innate Pharma Description and Business Overview
6.2.3 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.2.5 Innate Pharma Recent Developments/Updates
6.3 Corbus Pharmaceuticals
6.3.1 Corbus Pharmaceuticals Company Information
6.3.2 Corbus Pharmaceuticals Description and Business Overview
6.3.3 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.3.5 Corbus Pharmaceuticals Recent Developments/Updates
6.4 BioAtla
6.4.1 BioAtla Company Information
6.4.2 BioAtla Description and Business Overview
6.4.3 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.4.5 BioAtla Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Company Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Adcentrx Therapeutics
6.6.1 Adcentrx Therapeutics Company Information
6.6.2 Adcentrx Therapeutics Description and Business Overview
6.6.3 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.6.5 Adcentrx Therapeutics Recent Developments/Updates
6.7 Mabwell
6.7.1 Mabwell Company Information
6.7.2 Mabwell Description and Business Overview
6.7.3 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.7.5 Mabwell Recent Developments/Updates
6.8 Jiangsu Hengrui
6.8.1 Jiangsu Hengrui Company Information
6.8.2 Jiangsu Hengrui Description and Business Overview
6.8.3 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.8.5 Jiangsu Hengrui Recent Developments/Updates
6.9 Cspc Holdings
6.9.1 Cspc Holdings Company Information
6.9.2 Cspc Holdings Description and Business Overview
6.9.3 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolio
6.9.5 Cspc Holdings Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Industry Chain Analysis
7.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Production Mode & Process Analysis
7.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales and Marketing
7.4.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Channels
7.4.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors
7.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) Customer Analysis
8 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Dynamics
8.1 Nectin-4-Directed Antibody Drug Conjugates (ADC) Industry Trends
8.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Drivers
8.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Challenges
8.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism (US$ Million), 2025 vs 2032
Table 3. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody (US$ Million), 2025 vs 2032
Table 4. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competitive Situation by Manufacturers in 2025
Table 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Nectin-4-Directed Antibody Drug Conjugates (ADC), Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Product Types and Applications
Table 14. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2021–2026
Table 20. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2021–2026)
Table 21. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2027–2032
Table 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2027–2032)
Table 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2021–2026
Table 24. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2021–2026)
Table 25. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2027–2032
Table 26. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2027–2032)
Table 27. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026
Table 29. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032
Table 30. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026
Table 31. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026
Table 34. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032
Table 35. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026
Table 44. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032
Table 45. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032
Table 52. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Type (2021–2026)
Table 53. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Type (2027–2032)
Table 54. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021–2026)
Table 55. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2027–2032)
Table 56. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021–2026)
Table 59. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2027–2032)
Table 60. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2021–2026)
Table 61. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2027–2032)
Table 62. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Application (2021–2026)
Table 63. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Application (2027–2032)
Table 64. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021–2026)
Table 65. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2027–2032)
Table 66. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2021–2026)
Table 69. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2027–2032)
Table 70. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2021–2026)
Table 71. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2027–2032)
Table 72. Astellas Company Information
Table 73. Astellas Description and Business Overview
Table 74. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 76. Astellas Recent Developments/Updates
Table 77. Innate Pharma Company Information
Table 78. Innate Pharma Description and Business Overview
Table 79. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 81. Innate Pharma Recent Developments/Updates
Table 82. Corbus Pharmaceuticals Company Information
Table 83. Corbus Pharmaceuticals Description and Business Overview
Table 84. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 86. Corbus Pharmaceuticals Recent Developments/Updates
Table 87. BioAtla Company Information
Table 88. BioAtla Description and Business Overview
Table 89. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 91. BioAtla Recent Developments/Updates
Table 92. Eli Lilly Company Information
Table 93. Eli Lilly Description and Business Overview
Table 94. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 96. Eli Lilly Recent Developments/Updates
Table 97. Adcentrx Therapeutics Company Information
Table 98. Adcentrx Therapeutics Description and Business Overview
Table 99. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 101. Adcentrx Therapeutics Recent Developments/Updates
Table 102. Mabwell Company Information
Table 103. Mabwell Description and Business Overview
Table 104. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 106. Mabwell Recent Developments/Updates
Table 107. Jiangsu Hengrui Company Information
Table 108. Jiangsu Hengrui Description and Business Overview
Table 109. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 111. Jiangsu Hengrui Recent Developments/Updates
Table 112. Cspc Holdings Company Information
Table 113. Cspc Holdings Description and Business Overview
Table 114. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 116. Cspc Holdings Recent Developments/Updates
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors List
Table 120. Nectin-4-Directed Antibody Drug Conjugates (ADC) Customers List
Table 121. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Trends
Table 122. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Drivers
Table 123. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Challenges
Table 124. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Restraints
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Authors List of This Report
List of Figures
Figure 1. Product Picture of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Figure 2. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Type: 2025 & 2032
Figure 4. Cleavable Linkers Product Picture
Figure 5. Non-cleavable Linkers Product Picture
Figure 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism (US$ Million), 2021–2032
Figure 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Payload Mechanism: 2025 vs 2032
Figure 8. Microtubule inhibitors Product Picture
Figure 9. Topoisomerase Inhibitor Product Picture
Figure 10. Others Product Picture
Figure 11. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody (US$ Million), 2021–2032
Figure 12. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Antibody: 2025 vs 2032
Figure 13. Humanized IgG1 Product Picture
Figure 14. Fc Silencing IgG1 Product Picture
Figure 15. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application (US$ Million), 2021–2032
Figure 16. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Application: 2025 & 2032
Figure 17. Bladder Cancer
Figure 18. Esophageal Cancer
Figure 19. Triple-negative Breast Cancer
Figure 20. Others
Figure 21. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size (US$ Million), 2021–2032
Figure 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), 2021–2032
Figure 24. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price (US$/Unit), 2021–2032
Figure 25. Nectin-4-Directed Antibody Drug Conjugates (ADC) Report Years Considered
Figure 26. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Share by Manufacturers in 2025
Figure 27. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Share by Manufacturers in 2025
Figure 28. Top 5 and Top 10 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Players: Market Share by Revenue in Nectin-4-Directed Antibody Drug Conjugates (ADC) in 2025
Figure 29. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 30. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 31. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)
Figure 32. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)
Figure 33. United States Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Canada Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)
Figure 36. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)
Figure 37. Germany Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. France Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. U.K. Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Italy Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Russia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2021–2032)
Figure 43. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2021–2032)
Figure 44. China Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Japan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. South Korea Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. India Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Australia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. China Taiwan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Southeast Asia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)
Figure 52. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)
Figure 53. Mexico Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Brazil Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Argentina Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Colombia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)
Figure 58. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)
Figure 59. Turkey Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Saudi Arabia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. UAE Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Global Sales Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type (2021–2032)
Figure 63. Global Revenue Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type (2021–2032)
Figure 64. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2021–2032)
Figure 65. Global Sales Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application (2021–2032)
Figure 66. Global Revenue Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application (2021–2032)
Figure 67. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2021–2032)
Figure 68. Nectin-4-Directed Antibody Drug Conjugates (ADC) Value Chain
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Table 1. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism (US$ Million), 2025 vs 2032
Table 3. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody (US$ Million), 2025 vs 2032
Table 4. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Competitive Situation by Manufacturers in 2025
Table 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Nectin-4-Directed Antibody Drug Conjugates (ADC), Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Product Types and Applications
Table 14. Global Key Manufacturers of Nectin-4-Directed Antibody Drug Conjugates (ADC), Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2021–2026
Table 20. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2021–2026)
Table 21. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2027–2032
Table 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2027–2032)
Table 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2021–2026
Table 24. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2021–2026)
Table 25. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2027–2032
Table 26. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2027–2032)
Table 27. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026
Table 29. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032
Table 30. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026
Table 31. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026
Table 34. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032
Table 35. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026
Table 44. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032
Table 45. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (US$ Million), 2027–2032
Table 52. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Type (2021–2026)
Table 53. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Type (2027–2032)
Table 54. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021–2026)
Table 55. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2027–2032)
Table 56. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021–2026)
Table 59. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2027–2032)
Table 60. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2021–2026)
Table 61. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2027–2032)
Table 62. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Application (2021–2026)
Table 63. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units) by Application (2027–2032)
Table 64. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021–2026)
Table 65. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2027–2032)
Table 66. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2021–2026)
Table 69. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2027–2032)
Table 70. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2021–2026)
Table 71. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2027–2032)
Table 72. Astellas Company Information
Table 73. Astellas Description and Business Overview
Table 74. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 76. Astellas Recent Developments/Updates
Table 77. Innate Pharma Company Information
Table 78. Innate Pharma Description and Business Overview
Table 79. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 81. Innate Pharma Recent Developments/Updates
Table 82. Corbus Pharmaceuticals Company Information
Table 83. Corbus Pharmaceuticals Description and Business Overview
Table 84. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 86. Corbus Pharmaceuticals Recent Developments/Updates
Table 87. BioAtla Company Information
Table 88. BioAtla Description and Business Overview
Table 89. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 91. BioAtla Recent Developments/Updates
Table 92. Eli Lilly Company Information
Table 93. Eli Lilly Description and Business Overview
Table 94. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 96. Eli Lilly Recent Developments/Updates
Table 97. Adcentrx Therapeutics Company Information
Table 98. Adcentrx Therapeutics Description and Business Overview
Table 99. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 101. Adcentrx Therapeutics Recent Developments/Updates
Table 102. Mabwell Company Information
Table 103. Mabwell Description and Business Overview
Table 104. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 106. Mabwell Recent Developments/Updates
Table 107. Jiangsu Hengrui Company Information
Table 108. Jiangsu Hengrui Description and Business Overview
Table 109. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 111. Jiangsu Hengrui Recent Developments/Updates
Table 112. Cspc Holdings Company Information
Table 113. Cspc Holdings Description and Business Overview
Table 114. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product
Table 116. Cspc Holdings Recent Developments/Updates
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors List
Table 120. Nectin-4-Directed Antibody Drug Conjugates (ADC) Customers List
Table 121. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Trends
Table 122. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Drivers
Table 123. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Challenges
Table 124. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Restraints
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Authors List of This Report
List of Figures
Figure 1. Product Picture of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Figure 2. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Type: 2025 & 2032
Figure 4. Cleavable Linkers Product Picture
Figure 5. Non-cleavable Linkers Product Picture
Figure 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Payload Mechanism (US$ Million), 2021–2032
Figure 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Payload Mechanism: 2025 vs 2032
Figure 8. Microtubule inhibitors Product Picture
Figure 9. Topoisomerase Inhibitor Product Picture
Figure 10. Others Product Picture
Figure 11. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Antibody (US$ Million), 2021–2032
Figure 12. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Antibody: 2025 vs 2032
Figure 13. Humanized IgG1 Product Picture
Figure 14. Fc Silencing IgG1 Product Picture
Figure 15. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Value by Application (US$ Million), 2021–2032
Figure 16. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Application: 2025 & 2032
Figure 17. Bladder Cancer
Figure 18. Esophageal Cancer
Figure 19. Triple-negative Breast Cancer
Figure 20. Others
Figure 21. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size (US$ Million), 2021–2032
Figure 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), 2021–2032
Figure 24. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Average Price (US$/Unit), 2021–2032
Figure 25. Nectin-4-Directed Antibody Drug Conjugates (ADC) Report Years Considered
Figure 26. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Share by Manufacturers in 2025
Figure 27. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Share by Manufacturers in 2025
Figure 28. Top 5 and Top 10 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Players: Market Share by Revenue in Nectin-4-Directed Antibody Drug Conjugates (ADC) in 2025
Figure 29. Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 30. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 31. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)
Figure 32. North America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)
Figure 33. United States Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Canada Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)
Figure 36. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)
Figure 37. Germany Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. France Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. U.K. Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Italy Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Russia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2021–2032)
Figure 43. Asia Pacific Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2021–2032)
Figure 44. China Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Japan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. South Korea Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. India Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Australia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. China Taiwan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Southeast Asia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)
Figure 52. Latin America Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)
Figure 53. Mexico Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Brazil Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Argentina Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Colombia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021–2032)
Figure 58. Middle East and Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021–2032)
Figure 59. Turkey Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Saudi Arabia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. UAE Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Global Sales Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type (2021–2032)
Figure 63. Global Revenue Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Type (2021–2032)
Figure 64. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Type (2021–2032)
Figure 65. Global Sales Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application (2021–2032)
Figure 66. Global Revenue Market Share of Nectin-4-Directed Antibody Drug Conjugates (ADC) by Application (2021–2032)
Figure 67. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Price (US$/Unit) by Application (2021–2032)
Figure 68. Nectin-4-Directed Antibody Drug Conjugates (ADC) Value Chain
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Ethylene Oxide (EO) Market Research Report 2026
Jan 17, 26
Global Stem Cells Cryopreservation Equipments Market Research Report 2026
Jan 17, 26
Global Selenium-enriched Yeast Market Research Report 2026
Jan 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232